Merck Announces Interim Data for Merck's VICTRELISTM in Prior Null Responder Patients with Chronic Hepatitis C Genotype 1
Merck (NYSE: MRK) announced results of an interim analysis from the PROVIDE study, an open-label study examining the efficacy of VICTRELIS, the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor, in combination with peginterferon alfa and ribavirin in adult patients with chronic HCV genotype 1 who had a null response to prior P/R therapy. These patients are significantly less likely to respond to subsequent treatments. In this interim analysis, 38 percent (16/42) of prior null responders achieved a sustained virologic response 1 when treated with VICTRELIS in combination with P/R. These results, along with several new data analyses of VICTRELIS and MK-5172, Merck's investigational medicine for the treatment of chronic HCV, will be presented this week at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco.
“In the interim results of the PROVIDE study, approximately one-third of the patients who had a null response to prior peginterferon alfa and ribavirin therapy and failed treatment were able to achieve a sustained virologic response when retreated with VICTRELIS in combination therapy,” said John M. Vierling, M.D., F.A.C.P, professor of Medicine and Surgery at the Baylor College of Medicine in Houston, Texas, director of Baylor Liver Health and Chief of Hepatology, who presented the PROVIDE data. "Null responders are considered to be among the most difficult patients to treat, and we are encouraged by these data."
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.